Minerva Surgical (NASDAQ: UTRS) is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of abnormal uterine bleeding (AUB). The company’s flagship offering, the Minerva Endometrial Ablation System, employs a non-hysteroscopic, radiofrequency-based approach to deliver uniform thermal therapy to the endometrial lining. Designed for use in outpatient or office-based settings, the single-use device aims to reduce procedure time and improve patient comfort compared to traditional surgical techniques.
Founded in 2010 and headquartered in Redwood City, California, Minerva Surgical secured U.S. Food and Drug Administration (FDA) clearance for its endometrial ablation system in 2015. Since then, the company has built a dedicated research and development team to refine its technology platform and expand its clinical evidence base. Minerva’s R&D efforts include studies to evaluate long-term outcomes, procedural safety, and patient-reported satisfaction, with publications in peer-reviewed journals bolstering its clinical profile.
Minerva Surgical primarily serves gynecologists and women’s health specialists across the United States, with initial efforts underway to introduce the system into select international markets. Through strategic partnerships and distribution agreements, the company is exploring commercialization in Europe and other regions, leveraging a network of key opinion leaders and clinical investigators to drive adoption and education.
Under the leadership of President and CEO Jason McGraw, Minerva Surgical has assembled a management team with deep experience in medical device development, regulatory affairs, and commercial operations. The company remains committed to advancing women’s health through minimally invasive technologies and is actively pursuing pipeline opportunities to address unmet needs in gynecological care.
AI Generated. May Contain Errors.
